Our research focuses on using and developing the CRISPR/Cas9 system for precise gene editing in primary cells such as human T cells and hematopoietic stem and progenitor cells. In recent years, these cell types have become increasingly easier to manipulate with gene editing tools and we are now at a point where this technology can be used to study these cells in more depth or to genetically engineer cells for therapeutic purposes.